TScan Therapeutics (NASDAQ:TCRX) Issues Earnings Results

TScan Therapeutics (NASDAQ:TCRX) posted its earnings results on Monday. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.02, Zacks reports. TScan Therapeutics had a negative net margin of 653.50% and a negative return on equity of 61.13%. The firm had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $1.55 million.

TScan Therapeutics Stock Down 2.7 %

Shares of NASDAQ TCRX traded down $0.16 during trading on Wednesday, reaching $5.70. The company had a trading volume of 127,210 shares, compared to its average volume of 256,451. TScan Therapeutics has a 12-month low of $1.97 and a 12-month high of $9.69. The stock has a market cap of $301.32 million, a PE ratio of -4.61 and a beta of 0.83. The business’s 50-day moving average is $6.88 and its 200 day moving average is $7.17. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 0.19.

Analyst Ratings Changes

A number of research firms have recently commented on TCRX. Wedbush reiterated an “outperform” rating and set a $10.00 target price on shares of TScan Therapeutics in a research note on Monday. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a research note on Monday. BTIG Research assumed coverage on TScan Therapeutics in a research note on Thursday, May 16th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a report on Tuesday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $12.00.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.